Gan & Lee Pharmaceuticals.

This study is testing two new injectable medications (GZR102 given weekly and GZR18 given every two weeks) for adults with type 2 diabetes. It's for people whose current GLP-1 medication isn't controlling their blood sugar well enough, even if they're also taking diabetes pills. …

This large, late-stage study is testing whether a new injectable drug called GZR18 works better and is as safe as existing diabetes medications. It involves 1100 Chinese adults whose type 2 diabetes is not well-controlled with their current metformin-based pills. The main goal is…

This study is testing if a new weekly insulin injection (GZR4) works as well and is as safe as the standard daily insulin (glargine) for people with type 2 diabetes who haven't started insulin yet. It will involve about 580 participants and will compare how well each treatment co…

This study is testing if a new, once-weekly insulin injection called GZR4 is as effective and safe as a standard daily insulin for adults with type 2 diabetes. It will involve about 620 people who are already using a long-acting insulin. The main goal is to see which treatment be…

This study is testing if a new experimental insulin called GZR4, given just once a week, works as well and is as safe as the standard daily insulin injections for people with type 2 diabetes. It will involve about 580 adults who are already using a combination of long-acting and …

This study is testing whether a new injectable medication called GZR18 can help control blood sugar and body weight in Chinese adults with type 2 diabetes. It compares the drug to a placebo (dummy injection) in people whose blood sugar is still too high despite diet and exercise.…

This large, late-stage study is testing whether a new injection called GZR18 helps adults with obesity or overweight lose weight. About 630 participants in China will receive either the real injection or a placebo (dummy shot) to compare results. The main goal is to see how much …

This early-stage study aims to understand how a potential diabetes drug, GZR4 Injection, is processed by the body in people with varying degrees of liver impairment. It will enroll 36 adults, including those with mild, moderate, or severe liver damage, as well as people with norm…